Pharmaceutical Market Access in Emerging Markets

Dr Arturo Dr Schweiger, Kally Wong, Dr Debra Dr Leong

  • 出版商: ***
  • 出版日期: 2016-10-31
  • 售價: $1,260
  • 貴賓價: 9.5$1,197
  • 語言: 英文
  • 頁數: 238
  • 裝訂: Paperback
  • ISBN: 8897419631
  • ISBN-13: 9788897419631
  • 無法訂購

買這商品的人也買了...

商品描述

The definition of Market Access was first reported by the World Trade Organization as “to open markets for trade and improve transparency, reciprocity, and non-discrimination in international trade”. Pharmaceutical Market Access is different and it could be defined as achieving the optimal price for a product or service and/or the maximum reimbursement for the approved target population with no restrictions on funding for the medical technology. By the way, Market Access is not only the market authorization, but it also includes overlapping activities like pricing, health technology assessment, formulary, and reimbursement. Market Access is one of the most important activities for pharmaceutical companies and emerging countries represent an important opportunity for launching new products. It was reported that the Compounded Average Growth Rate (CAGR) was 6.0% in the period 2011-2017, and expected sales exceeding 1.1 trillion USD by 2017 for emerging countries. Furthermore, CAGR 2008-2012 for recently launched pharmaceuticals were 9.8% for emerging countries and 1.5% for the top 8 developed countries. The Market Access processes in the most important emerging countries in the selected regions are defined in this book with the aim to help local experts, local government officers, headquarter managements, and everyone who want to learn more about healthcare system and health policies pathways of Market Access, mapping and structure of decision makers, challenges and catalyzers for Market Access in the emerging countries.

商品描述(中文翻譯)

市場進入的定義首次由世界貿易組織報告,其意為「開放貿易市場,提高國際貿易的透明度、互惠性和非歧視性」。藥品市場進入則有所不同,可以定義為在批准的目標人口中實現產品或服務的最佳價格和/或最大的報銷金額,並且對醫療技術的資金沒有限制。此外,市場進入不僅僅是市場授權,還包括定價、健康技術評估、藥物清單和報銷等相互重疊的活動。市場進入是藥品公司最重要的活動之一,新興國家代表了推出新產品的重要機會。據報導,2011年至2017年期間的年均複合增長率(CAGR)為6.0%,預計到2017年新興國家的銷售額將超過1.1萬億美元。此外,2008年至2012年新近推出的藥品在新興國家的CAGR為9.8%,而在前8個發達國家則為1.5%。本書旨在介紹所選地區最重要的新興國家的市場進入流程,以幫助當地專家、政府官員、總部管理人員以及所有希望了解醫療系統和健康政策市場進入途徑、決策者的映射和結構、市場進入的挑戰和催化劑的人士。